AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 38390815 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin resistance (assessed by the insulin sensitivity index)
Number of subjects: 2752
Study 38390815 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic Blood Pressure (SBP)
Number of subjects: 2752
Study 38390815 — intervention group
Group type: EXPERIMENTAL
Intervention: Diastolic Blood Pressure (DBP)
Number of subjects: 2752
Study 38390815 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse Pressure (PP)
Number of subjects: 2752
Study 38390822 — intervention group
Group type: EXPERIMENTAL
Intervention: Optical coherence tomography-guided PCI
Number of subjects: 102
Study 38391195 — intervention group
Group type: EXPERIMENTAL
Intervention: PED with Shield technology
Number of subjects: 543
Study 38391195 — intervention group
Group type: COMPARATOR
Intervention: PED first-generation/PED Flex
Number of subjects: 543
Study 38391202 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy using azacitidine and nivolumab (Aza/Nivo)
Number of subjects: 0
Study 38391283 — intervention group
Group type: EXPERIMENTAL
Intervention: omega-3 fatty acid treatment
Number of subjects: 43
Study 38391283 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 43
Study 38391282 — intervention group
Group type: EXPERIMENTAL
Intervention: Early invasive mechanical ventilation (EIMV)
Number of subjects: 4464
Study 38391282 — intervention group
Group type: COMPARATOR
Intervention: Late invasive mechanical ventilation (LIMV)
Number of subjects: 4464
Study 38391311 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative US (QUS) radiomics data obtained after the 1st week of radiation therapy (RT)
Number of subjects: 55
Study 38391311 — intervention group
Group type: EXPERIMENTAL
Intervention: QUS analysis with gray-level co-occurrence matrix technique for textural analysis
Number of subjects: 55
Study 38391311 — intervention group
Group type: COMPARATOR
Intervention: Radiation therapy (RT) with a total dose of 70 Gy in 33-35 fractions over 6-7 weeks
Number of subjects: 55
Study 38393328 — intervention group
Group type: EXPERIMENTAL
Intervention: Benralizumab (30 mg)
Number of subjects: 140
Study 38393328 — intervention group
Group type: COMPARATOR
Intervention: Mepolizumab (300 mg)
Number of subjects: 140
Study 38393676 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin and clopidogrel or ticagrelor for 5 days
Number of subjects: 86
Study 38393694 — intervention group
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Number of subjects: 35
Study 38393694 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib+venetoclax
Number of subjects: 35
Study 38393723 — intervention group
Group type: EXPERIMENTAL
Intervention: Belzutifan 120 mg once daily
Number of subjects: 61
Study 38393755 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing educational intervention (4 sessions over 1 month, 1 week apart)
Number of subjects: 116
Study 38393755 — intervention group
Group type: COMPARATOR
Intervention: Usual care group
Number of subjects: 116
Study 38393754 — intervention group
Group type: EXPERIMENTAL
Intervention: Combustion-free nicotine alternatives (C-F NA)
Number of subjects: 0
Study 38393754 — intervention group
Group type: COMPARATOR
Intervention: Standard of care with brief cessation advice (control group; arm A)
Number of subjects: 0
Study 38393754 — intervention group
Group type: COMPARATOR
Intervention: Never smokers (reference group; arm C)
Number of subjects: 0
Study 38393761 — intervention group
Group type: EXPERIMENTAL
Intervention: 16-week individualized and supervised exercise program
Number of subjects: 200
Study 38393761 — intervention group
Group type: COMPARATOR
Intervention: Usual care (no intervention)
Number of subjects: 200
Study 38393773 — intervention group
Group type: EXPERIMENTAL
Intervention: MOON (serious video game intervention)
Number of subjects: 152
Study 38393773 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 152
Study 38394048 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical coconut-derived isosorbide diesters, dosage and duration not specified
Number of subjects: 0
Study 38394048 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical sunflower seed oil-derived isosorbide diesters, dosage and duration not specified
Number of subjects: 0
Study 38394048 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control, dosage and duration not specified
Number of subjects: 0
Study 38394113 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily notification prompts for physical activity (PA)
Number of subjects: 60
Study 38394113 — intervention group
Group type: COMPARATOR
Intervention: Control group (no prompts)
Number of subjects: 60
Study 38394119 — intervention group
Group type: EXPERIMENTAL
Intervention: Healer-led PPE training
Number of subjects: 136
Study 38394119 — intervention group
Group type: COMPARATOR
Intervention: HCW-led PPE training
Number of subjects: 136
Study 38394185 — intervention group
Group type: EXPERIMENTAL
Intervention: Online life skills programme
Number of subjects: 207
Study 38394185 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention during the study)
Number of subjects: 207
Study 38394279 — intervention group
Group type: EXPERIMENTAL
Intervention: BETTER transitional care intervention for 16 weeks post-hospital discharge
Number of subjects: 436
Study 38394279 — intervention group
Group type: COMPARATOR
Intervention: Usual transitional care management
Number of subjects: 436
Study 38394298 — intervention group
Group type: EXPERIMENTAL
Intervention: Schistoscope
Number of subjects: 1137
Study 38394298 — intervention group
Group type: COMPARATOR
Intervention: Conventional microscopy
Number of subjects: 1137
Study 38394353 — intervention group
Group type: EXPERIMENTAL
Intervention: CAD/CAM fixed retainers
Number of subjects: 181
Study 38394353 — intervention group
Group type: COMPARATOR
Intervention: Conventional multistranded fixed retainers
Number of subjects: 181
Study 38394384 — intervention group
Group type: EXPERIMENTAL
Intervention: Darolutamide
Number of subjects: 1509
Study 38394384 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1509
Study 38394387 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct oral anticoagulants (DOAC) treatment with measurement of DOAC levels
Number of subjects: 1657
Study 38394657 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukocyte- and platelet-rich fibrin (L-PRF)
Number of subjects: 350
Study 38394657 — intervention group
Group type: COMPARATOR
Intervention: Commercially available fibrin sealants (control)
Number of subjects: 350
Study 38394666 — intervention group
Group type: EXPERIMENTAL
Intervention: Daratumumab-carfilzomib-lenalidomide-dexamethasone (D-KRd) induction, autologous stem cell transplantation (ASCT), D-KRd consolidation, second ASCT, and daratumumab-lenalidomide maintenance.
Number of subjects: 50
Study 38394666 — intervention group
Group type: EXPERIMENTAL
Intervention: D-KRd induction/consolidation
Number of subjects: 50
Study 38394666 — intervention group
Group type: EXPERIMENTAL
Intervention: D-KRd with tandem transplant
Number of subjects: 50
Study 38394720 — intervention group
Group type: COMPARATOR
Intervention: DCD only (noASD)
Number of subjects: 102
Study 38394720 — intervention group
Group type: EXPERIMENTAL
Intervention: DCD and suspected ASD (sASD)
Number of subjects: 102
Study 38394720 — intervention group
Group type: EXPERIMENTAL
Intervention: DCD and confirmed ASD (cASD)
Number of subjects: 102
Study 38394720 — intervention group
Group type: EXPERIMENTAL
Intervention: Total group (DCD with and without ASD)
Number of subjects: 102
Study 38395023 — intervention group
Group type: EXPERIMENTAL
Intervention: Enabler mode
Number of subjects: 68
Study 38395023 — intervention group
Group type: EXPERIMENTAL
Intervention: Relayer mode
Number of subjects: 68
Study 38395023 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayer mode
Number of subjects: 68
Study 38395023 — intervention group
Group type: EXPERIMENTAL
Intervention: Decliner mode
Number of subjects: 68
Study 38395023 — intervention group
Group type: EXPERIMENTAL
Intervention: Persuader mode
Number of subjects: 68
Study 38395537 — intervention group
Group type: EXPERIMENTAL
Intervention: CAD-assisted colonoscopy
Number of subjects: 916
Study 38395537 — intervention group
Group type: COMPARATOR
Intervention: Conventional colonoscopy
Number of subjects: 916
Study 38395537 — intervention group
Group type: EXPERIMENTAL
Intervention: CAD first in tandem colonoscopy
Number of subjects: 916
Study 38395537 — intervention group
Group type: COMPARATOR
Intervention: Conventional colonoscopy first in tandem colonoscopy
Number of subjects: 916
Study 38395539 — intervention group
Group type: COMPARATOR
Intervention: Automated text messaging and monitoring (AMMI) only
Number of subjects: 1037
Study 38395539 — intervention group
Group type: EXPERIMENTAL
Intervention: AMMI plus peer support
Number of subjects: 1037
Study 38395539 — intervention group
Group type: EXPERIMENTAL
Intervention: AMMI plus strengths-based telehealth coaching
Number of subjects: 1037
Study 38395539 — intervention group
Group type: EXPERIMENTAL
Intervention: AMMI plus peer support and coaching
Number of subjects: 1037
Study 38395539 — intervention group
Group type: COMPARATOR
Intervention: Control group (AMMI only)
Number of subjects: 1037
Study 38395743 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle-integrated Functional Exercise Program (LiFE)
Number of subjects: 0
Study 38395743 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-delivered Lifestyle-integrated Functional Exercise Program (gLiFE)
Number of subjects: 0
Study 38395743 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study 38395743 — intervention group
Group type: EXPERIMENTAL
Intervention: LiFE
Number of subjects: 0
Study 38395743 — intervention group
Group type: EXPERIMENTAL
Intervention: gLiFE
Number of subjects: 0
Study 38395824 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP with intra-pocket application of diode laser (980 nm)
Number of subjects: 50
Study 38395824 — intervention group
Group type: COMPARATOR
Intervention: SRP with systemic antibiotic administration (spiramycin and metronidazole)
Number of subjects: 50
Study 38395833 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-EI (four-item exerciser identity measure)
Number of subjects: 1709
Study 38395833 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-HEI (four-item healthy-eater identity measure)
Number of subjects: 1709
Study 38395833 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-EI and 4-HEI in Successful weight loss category
Number of subjects: 1709
Study 38395833 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-EI and 4-HEI in Regain weight loss category
Number of subjects: 1709
Study 38395833 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-EI and 4-HEI in Unsuccessful weight loss category
Number of subjects: 1709
Study 38395833 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-EI and 4-HEI in maintaining ≥ 5% weight loss for > 1 year
Number of subjects: 1709
Study 38395833 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-EI and 4-HEI in not maintaining ≥ 5% weight loss for > 1 year
Number of subjects: 1709
Study 38395903 — intervention group
Group type: EXPERIMENTAL
Intervention: ONLOOP intervention (personalized reminders and toolkit)
Number of subjects: 862
Study 38395903 — intervention group
Group type: COMPARATOR
Intervention: Delayed intervention (control group)
Number of subjects: 862
Study 38395910 — intervention group
Group type: EXPERIMENTAL
Intervention: Interprofessional collaboration intervention for primary care physicians and nurses
Number of subjects: 0
Study 38395948 — intervention group
Group type: EXPERIMENTAL
Intervention: autologous natural dendritic cell (nDC)
Number of subjects: 148
Study 38395948 — intervention group
Group type: COMPARATOR
Intervention: placebo (PL)
Number of subjects: 148
Study 38395969 — intervention group
Group type: EXPERIMENTAL
Intervention: nDC treatment
Number of subjects: 148
Study 38395969 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 148
Study 38395980 — intervention group
Group type: EXPERIMENTAL
Intervention: tACS (transcranial electrical stimulation)
Number of subjects: 62
Study 38395980 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive training with tACS
Number of subjects: 62
Study 38395980 — intervention group
Group type: COMPARATOR
Intervention: Placebo stimulation
Number of subjects: 62
Study 38396126 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplementation with 90 mg vitamin C, 30 mg α-tocopherol (vitamin E), 18 mg vitamin B
Number of subjects: 0
Study 38396126 — intervention group
Group type: COMPARATOR
Intervention: Standard prenatal vitamin (control group)
Number of subjects: 0
Study 38396134 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable ultrasound device with carboplatin
Number of subjects: 33
Study 38396134 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin administration before sonication
Number of subjects: 33
Study 38396172 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor Treating Fields (TTFields) combined with CUSP9v3
Number of subjects: 0
Study 38396172 — intervention group
Group type: COMPARATOR
Intervention: CUSP9v3
Number of subjects: 0
Study 38396203 — intervention group
Group type: EXPERIMENTAL
Intervention: MENQOL intervention
Number of subjects: 1022
Study 38396300 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined vincristine, doxorubicin, cyclophosphamide, and etoposide (regimen I) plus radiation therapy (RT) for stage II/III disease.
Number of subjects: 132
Study 38396300 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen UH-1 (carboplatin added for stage IV disease, RT omitted for stage I if lymph nodes were sampled).
Number of subjects: 132
Study 38396300 — intervention group
Group type: COMPARATOR
Intervention: AREN03B2 stage-appropriate chemotherapy.
Number of subjects: 132
Study 38396300 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined studies for stage I (n=10), II (n=47), III (n=65), and IV (n=10) disease.
Number of subjects: 132
Study 38396300 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment without RT for stage I disease.
Number of subjects: 132
Study 38396300 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin-containing regimen for stage IV disease.
Number of subjects: 132
Study 38396455 — intervention group
Group type: EXPERIMENTAL
Intervention: HER2 positivity
Number of subjects: 200
Study 38396455 — intervention group
Group type: EXPERIMENTAL
Intervention: Ki-67 ≥ 20%
Number of subjects: 200
Study 38398474 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical bowel preparation and oral antibiotics
Number of subjects: 0
Study 38398474 — intervention group
Group type: COMPARATOR
Intervention: Control group (no mechanical bowel preparation and oral antibiotics)
Number of subjects: 0
Study 38398703 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic, latent toxoplasmosis treatment
Number of subjects: 0
Study 38398703 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 38400102 — intervention group
Group type: EXPERIMENTAL
Intervention: Monovalent Omicron XBB.1.5-adapted BNT162b2 (single 30-μg dose)
Number of subjects: 0
Study 38400158 — intervention group
Group type: EXPERIMENTAL
Intervention: SCTV01E-2
Number of subjects: 429
Study 38400158 — intervention group
Group type: COMPARATOR
Intervention: SCTV01E
Number of subjects: 429
Study 38400193 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad26.ZEBOV and MVA-BN-Filo vaccines
Number of subjects: 614
Study 38400200 — intervention group
Group type: EXPERIMENTAL
Intervention: sIPV primary vaccination
Number of subjects: 0
Study 38400200 — intervention group
Group type: EXPERIMENTAL
Intervention: sIPV booster vaccination
Number of subjects: 0
Study 38400200 — intervention group
Group type: EXPERIMENTAL
Intervention: sIPV priming and booster vaccination
Number of subjects: 0
Study 38400528 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-reported QoL
Number of subjects: 146
Study 38400528 — intervention group
Group type: EXPERIMENTAL
Intervention: Proxy-reported QoL
Number of subjects: 146
Study 38400570 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoposide, cytarabine, and pegfilgrastim (EAP) regimen
Number of subjects: 0
Study 38400780 — intervention group
Group type: EXPERIMENTAL
Intervention: ONC201 administered D1D2 (twice-weekly)
Number of subjects: 12
Study 38400780 — intervention group
Group type: COMPARATOR
Intervention: ONC201 administered once-weekly (D1)
Number of subjects: 12
Study 38400813 — intervention group
Group type: EXPERIMENTAL
Intervention: Staccato alprazolam 1 mg
Number of subjects: 36
Study 38400813 — intervention group
Group type: EXPERIMENTAL
Intervention: Staccato alprazolam 2 mg
Number of subjects: 36
Study 38400813 — intervention group
Group type: COMPARATOR
Intervention: Staccato placebo
Number of subjects: 36
Study 38400905 — intervention group
Group type: EXPERIMENTAL
Intervention: Proactive financial navigation (FN) intervention
Number of subjects: 31
Study 38400905 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 31
Study 38400914 — intervention group
Group type: EXPERIMENTAL
Intervention: zilucoplan 0.3 mg/kg
Number of subjects: 174
Study 38400914 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 174
Study 38400919 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine gum (300 mg)
Number of subjects: 36
Study 38400919 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 38400942 — intervention group
Group type: EXPERIMENTAL
Intervention: CORE®
Number of subjects: 20
Study 38400942 — intervention group
Group type: EXPERIMENTAL
Intervention: Everion®
Number of subjects: 20
Study 38400984 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated Care Approach for Breast Cancer Patients
Number of subjects: 0
Study 38401036 — intervention group
Group type: EXPERIMENTAL
Intervention: L-Glutamine (0.1 g/kg twice daily, 0.3 g/kg twice daily, 0.6 g/kg once daily)
Number of subjects: 12
Study 38401036 — intervention group
Group type: EXPERIMENTAL
Intervention: L-Glutamine (multiple doses over 3 weeks)
Number of subjects: 12
Study 38401036 — intervention group
Group type: EXPERIMENTAL
Intervention: L-Glutamine (oral therapy)
Number of subjects: 12
Study 38401078 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirulina (1.6g/day for 2 months)
Number of subjects: 43
Study 38401078 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 38401202 — intervention group
Group type: EXPERIMENTAL
Intervention: Satralizumab
Number of subjects: 131
Study 38401551 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyriproxyfen-pyrethroid LLINs
Number of subjects: 600
Study 38401551 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorfenapyr-pyrethroid LLINs
Number of subjects: 600
Study 38401551 — intervention group
Group type: COMPARATOR
Intervention: Pyrethroid-only LLINs (reference group)
Number of subjects: 600
Study 38401646 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Number of subjects: 2602
Study 38401647 — intervention group
Group type: EXPERIMENTAL
Intervention: NOAC monotherapy
Number of subjects: 960
Study 38401647 — intervention group
Group type: COMPARATOR
Intervention: NOAC plus clopidogrel combination therapy
Number of subjects: 960
Study 38401649 — intervention group
Group type: EXPERIMENTAL
Intervention: Early UFH administration (iv. bolus of 100 units/kg UFH)
Number of subjects: 410
Study 38401649 — intervention group
Group type: EXPERIMENTAL
Intervention: Late UFH administration (iv. bolus of 100 units/kg UFH)
Number of subjects: 410
Study 38401649 — intervention group
Group type: COMPARATOR
Intervention: Placebo (given after obtaining femoral vein access and at least 5 minutes prior to the start of the TSP)
Number of subjects: 410
Study 38401649 — intervention group
Group type: COMPARATOR
Intervention: Placebo (given immediately after TSP)
Number of subjects: 410
Study 38401691 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy-restricted diets with different nutrient compositions
Number of subjects: 0
Study 38401691 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 38401741 — intervention group
Group type: EXPERIMENTAL
Intervention: FODMAP powders (fructans, fructose, galacto-oligosaccharides, lactose, mannitol, sorbitol)
Number of subjects: 117
Study 38401741 — intervention group
Group type: COMPARATOR
Intervention: Control (glucose)
Number of subjects: 117
Study 38401785 — intervention group
Group type: EXPERIMENTAL
Intervention: care gap
Number of subjects: 13346
Study 38401785 — intervention group
Group type: EXPERIMENTAL
Intervention: alert
Number of subjects: 13346
Study 38401785 — intervention group
Group type: EXPERIMENTAL
Intervention: both (care gap and alert)
Number of subjects: 13346
Study 38401785 — intervention group
Group type: COMPARATOR
Intervention: standard practice (control arm)
Number of subjects: 13346
Study 38401789 — intervention group
Group type: COMPARATOR
Intervention: Multiple family group-based family strengthening intervention
Number of subjects: 89
Study 38401789 — intervention group
Group type: COMPARATOR
Intervention: Group cognitive behavioral therapy intervention
Number of subjects: 89
Study 38401796 — intervention group
Group type: EXPERIMENTAL
Intervention: FSIQ-RMS Symptoms domain
Number of subjects: 0
Study 38401796 — intervention group
Group type: EXPERIMENTAL
Intervention: FSIQ-RMS Physical Impacts domain
Number of subjects: 0
Study 38401796 — intervention group
Group type: EXPERIMENTAL
Intervention: FSIQ-RMS Cognitive/Emotional Impacts domain
Number of subjects: 0
Study 38401796 — intervention group
Group type: EXPERIMENTAL
Intervention: FSIQ-RMS Coping Impacts domain
Number of subjects: 0
Study 38401897 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation programme (CardioActive; CA) plus usual care
Number of subjects: 100
Study 38401897 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 100
Study 38401894 — intervention group
Group type: EXPERIMENTAL
Intervention: MS CATCH for 12 months
Number of subjects: 125
Study 38401894 — intervention group
Group type: COMPARATOR
Intervention: Usual care for 6 months, then MS CATCH for 6 months
Number of subjects: 125
Study 38401894 — intervention group
Group type: EXPERIMENTAL
Intervention: MS CATCH
Number of subjects: 125
Study 38401903 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-Intensive Care Syndrome interventions (specifics not provided)
Number of subjects: 0
Study 38402053 — intervention group
Group type: EXPERIMENTAL
Intervention: Start to move protocol
Number of subjects: 69
Study 38402053 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 69
Study 38402046 — intervention group
Group type: EXPERIMENTAL
Intervention: LDR brachytherapy
Number of subjects: 35
Study 38402046 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (no brachytherapy)
Number of subjects: 35